Format

Send to

Choose Destination
Pharmacogenomics. 2019 Aug;20(13):939-946. doi: 10.2217/pgs-2019-0079.

CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus.

Author information

1
Vanderbilt University School of Medicine, UCSF, Nashville, TN 37232, USA.
2
Department of Pediatrics, Vanderbilt University Medical Center, UCSF, Nashville, TN 37232, USA.
3
Department of Medicine, Vanderbilt University Medical Center, UCSF, Nashville, TN 37232, USA.
4
Department of Pediatrics & Cardiovascular Research Center, University of California San Francisco, San Francisco, CA 94143, USA.
5
Department of Pediatrics, University of Iowa, Iowa City, UMKC, IA 52242, USA.
6
Department of Epidemiology, University of Iowa, Iowa City, UMKC, IA 52242, USA.
7
Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, MO 64110, USA.

Abstract

Aims: To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). Patients & Methods: This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. Results: In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and CYP2C9*2 (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. Conclusion: Age, surfactant use, and CYP2C9*2 influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.

KEYWORDS:

ductus arteriosus; genetics; indomethacin; newborn; pharmacogenomics

PMID:
31486736
DOI:
10.2217/pgs-2019-0079

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center